Mark Muscat

Mark Muscat

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MMMark Muscat
Mark Muscat
MMMyriam Corinne Ben Mamou
Myriam Corinne Ben Mamou
CKCatharina Reynen-de Kat
Catharina Reynen-de Kat
DJDragan Jankovic
Dragan Jankovic
JHJose Hagan
Jose Hagan
SDSiddhartha Sankar Sankar Datta
Siddhartha Sankar Sankar Datta
The elimination of both measles and rubella remains a priority for all 53 Member States of the World Health Organization (WHO) European Region. To provide an update on the epidemiological status of measles and rubella in the Region, we reviewed surveillance data on both diseases for 2023 submitted monthly by national surveillance institutions. We analyzed the cases of measles and rubella for 2023 by age group, case classification, vaccination, hospitalization, and importation status and report on measles-related deaths. In 2023, 60,860 measles cases, including 13 fatal cases, were reported in 41 countries. Most cases (95%; n = 57,584) were reported by six countries: Azerbaijan, Kazakhstan, Kyrgyzstan, Romania, the Russian Federation, and Türkiye. Of the 60,848 cases with data on age, 19,137 (31%) were 1–4 years old and 12,838 (21%) were 5–9 years old. A total of 10,412 (17%) were 20 years and older. The genotypes identified in the Region were largely dominated by D8 variants (n = 1357) and the remainder were B3 variants (n = 221). In 2023, 345 rubella cases were reported by 17 countries, mostly from Poland, Kyrgyzstan, Tajikistan, Türkiye, and Ukraine. A total of 262 cases (76%) were classified as clinically compatible and 79 (23%) were laboratory-confirmed. To achieve the elimination of measles and rubella in the Region, political commitment needs to be revived to enable urgent efforts to increase vaccination coverage, improve surveillance and outbreak preparedness, and respond immediately to outbreaks.

24 February 2022 in Eurosurveillance
Verified
Journal Article
Open access
MMMark Muscat
Mark Muscat
BGBelete Gebrie
Belete Gebrie
AEAndroulla Efstratiou
Androulla Efstratiou
SDSiddhartha S Datta
Siddhartha S Datta
DDDanni Daniels
Danni Daniels
Background: Diphtheria is uncommon in the World Health Organization (WHO) European Region. Nevertheless, sporadic cases, sometimes fatal, continue to be reported. Aim: To report on diphtheria cases and coverage with first and third doses of diphtheria, tetanus and pertussis vaccines (DTP1 and DTP3, respectively) for 2010–19 in the Region with a focus on 2019. Methods: Data on diphtheria cases were obtained from WHO/United Nations International Children's Emergency Fund (UNICEF) Joint Reporting Forms submitted annually by the Region’s Member States. WHO/UNICEF Estimates of National Immunization Coverage for DTP1 and DTP3 were summarised for 2010–19. For 2019, we analysed data on age, and vaccination status and present data by country on DTP1 and DTP3 coverage and the percentage of districts with ≥ 90% and < 80% DTP3 coverage. Results: For 2010–19, 451 diphtheria cases were reported in the Region. DTP1 and DTP3 coverage was 92–96% and 95–97%, respectively. For 2019, 52 cases were reported by 11 of 48 countries that submitted reports (including zero reporting). Thirty-nine countries submitted data on percentage of their districts with ≥ 90% and < 80% DTP3 coverage; 26 had ≥ 90% districts with ≥ 90% coverage while 11 had 1–40% districts with < 80% coverage. Conclusion: Long-standing high DTP3 coverage at Regional level probably explains the relatively few diphtheria cases reported in the Region. Suboptimal surveillance systems and inadequate laboratory diagnostic capacity may also be contributing factors. Still, the observed cases are of concern. Attaining high DTP3 coverage in all districts and implementing recommended booster doses are necessary to control diphtheria and prevent outbreaks.

6 April 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SDSiddhartha Sankar Sankar Datta
Siddhartha Sankar Sankar Datta
Federico Martinón-TorresFederico Martinón-Torres
Federico Martinón-Torres
NBNino Berdzuli
Nino Berdzuli
NCNiyazi Cakmak
Niyazi Cakmak
MEMichael Edelstein
Michael Edelstein
MMMark Muscat
Mark Muscat
Universal immunization substantially reduces morbidity and mortality from vaccine-preventable diseases. In recent years, routine immunization coverage has varied considerably among countries across the WHO European Region, and among different populations and districts within countries. It has even declined in some countries. Sub-optimal immunization coverage contributes to accumulations of susceptible individuals and can lead to outbreaks of vaccine-preventable diseases. The European Immunization Agenda 2030 (EIA2030) seeks to build better health in the WHO European Region by ensuring equity in immunization and supporting immunization stakeholders in devising local solutions to local challenges. The factors that influence routine immunization uptake are context specific and multifactorial; addressing immunization inequities will require overcoming or removing barriers to vaccination for underserved individuals or populations. Local level immunization stakeholders must first identify the underlying causes of inequities, and based on this information, tailor resources, or service provision to the local context, as per the organization and characteristics of the health care system in their countries. To do this, in addition to using the tools already available to broadly identify immunization inequities at the national and regional levels, they will need new pragmatic guidance and tools to address the identified local challenges. It is time to develop the necessary guidance and tools and support immunization stakeholders at all levels, especially those at the subnational or local health centre levels, to make the vision of EIA2030 a reality.

8 January 2009 in Eurosurveillance
Verified
Journal Article
Open access
BKB Kaic
B Kaic
IGI Gjenero-Margan
I Gjenero-Margan
SKS Kurečić-Filipović
S Kurečić-Filipović
MMMark Muscat
Mark Muscat
We report an outbreak of measles in Croatia, involving 49 cases with onset of symptoms between end of April and June 2008. Cases occurred in Zagreb and Slavonski Brod but investigations indicated a common epidemiological link between these two geographically separate regions.

10 July 2025 in Eurosurveillance
Verified
Journal Article
Open access
ABAnja Berger
Anja Berger
ADAlexandra Dangel
Alexandra Dangel
KBKatja Bengs
Katja Bengs
SSSandra Schlotmann
Sandra Schlotmann
PTPeter Thomaßen
Peter Thomaßen
ASAndreas Sing
Andreas Sing
In September 2024, a school-aged child (P1), unvaccinated against diphtheria, was hospitalised with severe respiratory diphtheria caused by toxigenic Corynebacterium diphtheriae. P1 subsequently died from the disease. The child’s mother (P2) had pharyngitis 9 days before the onset of symptoms of P1 and subsequently tested positive for C. diphtheriae . In multilocus sequence typing (MLST), the C. diphtheriae isolates from P1 and P2 were of sequence type (ST) 574. In core genome (cg)MLST, they were clonal, suggesting recent human-to-human transmission. This indicates the first autochthonous respiratory diphtheria outbreak by toxigenic C. diphtheriae in Germany since 1984 with epidemiologically- and molecularly-confirmed transmission. Furthermore, the isolates were close to isolates from patients with cutaneous diphtheria among people experiencing homelessness in two major German cities in 2023 and 2024, and to isolates from an outbreak among newly arriving migrants across several European countries, including Germany, detected in 2022. This indicates transmission beyond vulnerable groups. Our findings illustrate the potential of C. diphtheriae spreading further from patients with cutaneous diphtheria and even causing outbreaks of respiratory diphtheria. Given the potentially serious complications of respiratory diphtheria, including death, equitably achieving and maintaining high vaccination coverage among the whole population, especially among vulnerable people is essential.

18 March 2019 in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Verified
Journal Article
Closed access
PDF file
MMMark Muscat
Mark Muscat
MMMyriam Ben Mamou
Myriam Ben Mamou
SSSimarjit Singh
Simarjit Singh
CKCatharina de Kat
Catharina de Kat
DJDragan Jankovic
Dragan Jankovic
POPatrick O’cOnnor
Patrick O’cOnnor